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Modern treatment of the 
systemic fungus diseases 
For many years the systemic funglls diseases received little attention from the members 
of the medical profession and in the cttrriculum of the medical schools in the United States. 
Recently there has been a gradual awakening to their importance. The introduction 
of increasing numbers of antifungal chemotherapeutic agents attest this new interest 
in the mycotic diseases. Beneficial or curative specific therapy is now possible for 
many of these diseases which previollsly were without effective means of treatment. 
E. Richard Harrell, M.D., and Florante C. Bocobo, M.D. Ann Arbor, Mich. 
Department of Dermatology, University of Michigan "Medical Center 
The systemic fungus diseases are not 
common, and it is difficult to amass a sig-
nificant number of patients with anyone 
specific deep mycosis in order to evaluate 
clinically any new chemotherapeutic agent. 
This review has attempted to assemble and 
summarize the present-day knowledge of 
the newer antifungal agents. Individual 
consideration is given to the systemic fun-
gus diseases: coccidioidomycosis, histoplas-
mosis, North American blastomycosis, South 
American blastomycosis, cryptococcosis, ac-
tinomycosis, nocardiosis, sporotrichosis, can-
didiasis, aspergillosis, and mucormycosis. 
Other contaminant fungi, such as species of 
Penicillium and Geotrichum, which at times 
assume a pathogenic role and cause disease, 
are not given individual consideration in 
this paper. 
Since amphotericin B has given the most 
encouraging results of all the antifungal 
agents, greater attention is devoted to this 
antibiotic in this review. 
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Amphotericin B 
Amphotericin B'" is a polyene, antifungal 
antibiotic produced by a strain (M 457 4) of 
Streptomyces nodosus which was found in 
a soil sample obtained at Tembladora near 
the Orinoco River in Venezuela. It was first 
isolated and described by Gold, Stout, Pag-
ano and Donovick1 in 1955 and further 
characterized by others.2-6 
Extraction of the whole culture broth in 
which the streptomycete is grown, or of the 
mycelial mat itself, yields a yellowish crude 
product containing amphotericin B, to-
gether with another active principle labeled 
amphotericin A. The extracting solvents 
used are water-saturated butanol; any of the 
lower alcohols, such as methanol, propanol, 
and, perferably, isopropanol; a water mis-
cible solvent, like N,N-dimethylformamide 
or dimethyl sulfoxide. The two active prin-
ciples may be separated from each other 
and purified by differential solution and 
precipitation. Further differentiation may 
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be accomplished by specific optical rotation 
and ultraviolet absorption curves. 
Physical and chemical properties.1 ,4-7 
Amphotericin B is a yellowish powder 
which is relatively insoluble. It is insoluble 
in anhydrous alcohols, acetone, ethers, chlo-
roform, benzene, toluene, ethyl acetate, gla-
cial acetic acid, pyridine, or alcoholic po-
tassium hydroxide. It is soluble only to a 
small extent in water at pH 2 and pH 11. 
Solubilized preparations, however, in the 
form of colloidal dispersions suitable for 
biologic work, have been made possible 
with the use of sodium desoxycholate. A 
melting point cannot be determined as the 
compound darkens and decomposes gradu-
ally above 170°C. The specific optical rota-
tion in 0.1 methyl hydroxide-hydrochloric 
acid [a] D 23,5C is -33.6 and in acid dimethyl-
formamide [a] D 23.5C, +333. Its ultraviolet 
absorption curve is characteristic of a oon-
jugated heptaene, like ascosin or tricho-
mycin. The curve of amphotericin A is that 
of a conjugated tetra ene, like rimocidin or 
nystatin. 
Amphotericin B is amphoteric. The neu-
tralization equivalent when it is titrated as 
a base is 929. It gives a negative ferric chlo-
ride test and a positive Molisch test and de-
colorizes potassium permanganate or bro-
mide-carbon tetrachloride. Elementary an-
alysis shows carbon, hydrogen, and nitro-
gen, but not halogen, sulfur, methoxyl or 
acetyl groups. The empirical formula of 
C46H7302o has been tentatively assigned to 
it. Evidence indicates a basic moiety of 
aminodesoxyhexose, for which the name 
"mycosamine" has been proposed. 
Assay methods.I ,6,s-ll With the increasing 
use of amphotericin B, bioassay methods to 
determine the amounts of the drug in bio-
logic fluids have been described, utilizing 
essentially the tube serial dilution technique 
or the agar diffusion method. These meth-
ods have not been standardized as yet. The 
test organisms used are Candida albicans, 
Histoplasma capsulatum, and Saccharomy-
ces cerevisiae. Growth inhibition is meas-
ured by visual turbidity readings, turbidi-
metric determinations with the spectropho-
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tometer, or direct counts of the organisms 
in a hemocytometer chamber. 
Absorption, distribution, and excretion. 
Amphotericin B is poorly absorbed through 
the gastrointestinal tract in mice,12,13 in 
dogs,14 and in man.6,S,12 Only maximal val-
ues of 0.03 to 0.08 p.g per milliliter plasma 
were obtained in dogs 18 hours after a 
single oral dose of SOO mg. of amphotericin 
B. None was detected in the heart, liver, 
or spleen. Only 0.1 per cent of the daily 
dose was excreted in the urine during a 5 
hour period, and 6S to 87 per cent was re-
covered from the stools during one 24 hour 
period.14 In 13 patients given oral ampho-
tericin B, the blood levels found were low. 
The spinal fluid frequently showed none, 
or very small amounts, of the drug. Only 
small quantities appeared in the urine.s 
Clinical experience has shown that in pa-
tients who did not respond to the oral, sub-
cutaneous, or even intramuscular adminis-
tration of amphotericin B, assayable serum 
levels of the drug with resultant favorable 
clinical response could be achieved by in-
travenous infusion.6,S,IO,15 The blood level 
dropped considerably during the first 24 
hours after intravenous administration, then 
gradually thereafter. It was still possible to 
demonstrate serum levels a month laterY 
The spinal fluid level is low, being 1/30 to 
1/S0 of the serum levels. The excretion 
through the urine is small and slow. 
Toxicity in animals.3 ,16 In acute toxicity 
studies with intravenous solubilized ampho-
tericin B, the estimated lowest lethal dose 
(LD2) and mean lethal dose (LD50) for 
mice were 1.8 and 2.3 mg. per kilogram of 
body weight and 4.0 and 4.3 mg. per kilo-
gram of body weight, respectively. In 
chronic toxicity studies, no toxic evidence 
was observed in two groups of SO mice each 
given amphotericin B intraperitoneally in 
daily doses of from 5 to 100 mg. per kilo-
gram of body weight for SO and 71 days, 
respectively. 
Apparently there are species differences. 
In rabbits, 62 per cent of 19 animals died 
10 to 30 minutes after intravenous adminis-
tration of S.O to 6.6 mg. per kilogram of 
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body weight. Death was preceded by a rise 
in the blood urea nitrogen and by tremors 
and convulsions. In dogs, intravenous doses 
as low as 1.0 mg. per kilogram of body 
weight elicited 'an unusual and specific in-
testinal reaction, with anorexia, emesis, 
hematemesis, and bloody diarrhea. Autopsy 
showed hemorrhagic involvement of the 
duodenum primarily. Three of 4 monkeys 
given 2.0 mg. per kilogram of body weight 
per day intravenously 5 days a week for 3 
to 4 weeks showed neither acute nor de-
layed toxicity, except for .occasional vomit-
ing, sclerosis of veins, and elevation of the 
blood urea nitrogen.7 
Toxicity in man. Oral amphotericin B is 
relatively nontoxic and, except for occa-
sional mild gastrointestinal upsets, it is well 
tolerated, even in relatively large doses. 
When given intravenously the drug is more 
toxic, with a maximal tolerated dose of 1.0 
to 1.6 mg. per kilogram of body weight. The 
chief toxic effects. encountered are fever, 
nausea, emesis, anorexia, and azotemia, 
with the appearance of cellular and granu-
lar casts in the urine, as well as hematuria 
and proteinuria. The renal t.oxicity produced 
by amphotericin B represents the most seri-
ous drawback to the use of this antibiotic. 
The rise in the blood urea nitrogen which 
may occur during intravenous therapy is 
temporary and, after 2 to 7 days' rest, nor-
mal values are obtained. The antibi.otic ther-
apy can then be safely continued. The other 
toxic manifestations can be partially con-
trolled by the use of chlorpromazine in a 
dosage of 50 mg. administered prior to the 
amphotericin B therapy, and soluble hydr.o-
cortisone in a dosage of 20 mg. administered 
with the intravenous amphotericin B sus-
pension. There is question as to the wisdom 
of administering steroid hormones toO pa-
tients with granulomatous disease; how-
ever, there has not yet been evidence of 
undesirable effect. The intravenous solution 
of amphotericin B should be administered 
by slow drip, and adjusted s.o that a mini-
mum of 6 hours is required for the full 
daily dose. Toxicity can be minimized by 
strict attention to this simple procedure. 
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The drug is best tolerated if administered 
every other day, rather than on consecutive 
days. 
Antifungal spectrum. The results of the 
early in vitro studies1·3,12,13,17 indicating 
marked fungicidal action of amphotericin 
B against a wide variety of pathogenic 
fungi, especially the systemic species Can-
dida albicans, Cryptococcus neoformans, 
Blastomyces dermatitidis, Blastomyces bra-
siliensis, Sporotrichum schenckii, and Histo-
plasma capsulatum, have been substanti-
ated by favorable findings in laboratory 
animal infections,3,12,13,18.20 and by an ex-
panding clinical experience in the treatment 
of human infecti.ons due to these fungi. 
Amphotericin B has no significant antibac-
terial activity. 
Dosage and administration. The mostef-
fective mode of administration is by intra-
venous infusion. The parenteral soluble 
preparation of the drug comes as a sterile, 
lyophilized powder in vials each containing 
50 mg. of amph.otericin Band 41 mg. of 
sodium desoxycholate with a sodium phos-
phate buffer. Inasmuch as saline solution 
causes precipitation of the antibiotic, the 
recommended solvent is 5 per cent dextrose 
in water. The optimum concentrati.on is be-
tween 0.1 mg. and 0.5 mg. per milliliter 
solution. 
The optimum adult dose is 50 mg. per 
day, although the drug should be initially 
given at a dose of 25 mg. per day and grad-
ually increased, depending upon the reac-
tion of the patient. If toxicity develops with 
daily administration, the drug may be given 
on alternate days, or even stopped tempo-
rarily and resumed at a lower dosage level. 
The treatment course usually runs from 20 
to 60 days, but may be longer if the clinical 
response of the patient is not satisfactory 
within that period. 
When especially indicated, amphotericin 
B may be administered orally (2 to 10 Cm. 
daily), intra the cally (up to 1 mg. every 
other day), intramuscularly, intra-articu-
larly (up toO 25 mg. every other day), as an 
aerosol intrapulmonary spray (5 mg. every 
6 hours), intrathoracically (up to 3 mg. ), or 
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into the cutaneous lesions (up to 25 mg. 
with 2 per cent procaine every other day).21 
Coccidioidomycosis 
Coccidioidomycosis is one of the most 
prevalent and important of the deep my-
coses. It is caused by Coccidioides immitis, 
a fungus indigenous to the arid regions of 
the southwestern United States. The prin-
cipal focus of coccidioidomycosis is loca-
lized to the San Joaquin Valley of Califor-
nia, with known endemic areas in Nevada, 
Arizona, New Mexico, Texas, and northern 
Mexico.22 Although the disease is acquired 
only in these areas, it has become a prob-
lem to all physicians regardless of their 
geographic location, for travel ultimately 
takes a large percentage of the United 
States population into the endemic areas. 
The arthrospore phase of Coccidioides im-
mitis has been isolated from soil specimens, 
especially those taken from the burrows of 
desert rodents. These animals may serve as 
the reservoir for this disease.23 ,24 Once in-
fection develops in the human, the arthro-
spore, or vegetative phase of Coccidioides 
immitis, changes to a spherule stage. The 
spherule, which is laden with endospores, is 
seen on microscopic examination of in-
fected human tissue. The organisms, which 
are quite characteristic in their shape, are 
normally 20 to 80 }L in diameter.25 These 
spherules grow quite readily on artificial 
agar, producing a Huffy, white to brownish-
white aerial hyphal growth, which segments 
into closely jointed structures called arthro-
spores. Such cultures are highly infectious 
and must be handled with great care by 
laboratory personneJ.26 There has been no 
known instance of human-to-human trans-
mission of this disease. 
Except for the rare instance of primary 
cutaneous inoculation ooccidioidomycosis, 
the disease is acquired by inhalation of the 
causative arthrospore. When cutaneous in-
oculation occurs, a primary ulcerative gran-
uloma resembling primary inoculation tu-
berculosis develops at the site of the inocu-
lation. Satellite lymphadenopathy then de-
velops, and the disease has been reported 
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to run a completely benign course without 
evidence of dissemination.27 Following in-
halation of the causative agent by a previ-
ously uninfected person, the disease is 
usually confined to a focal area of the lungs, 
producing such mild disease that 70 per 
cent of the cases remain subclinical and 
unrecognized.22 When symptoms occur, 
they are those of upper respiratory infec-
tion, usually revealing on roentgenograms 
of the chest areas of patchy infiltration, 
nodular infiltration, and pneumonitis, along 
with occasional pleural effusion and hilar 
lymphadenopathy. This type of patient may 
develop allergic manifestations such as ery-
thema nodosum, erythema multiforme, or 
urticarial eruptions. Total healing takes 
place within a matter of several weeks to 
several months. Approximately 5 per cent 
of patients who have severe primary pul-
monary coccidioidomycosis will be left with 
residual manifestations, consisting of thin-
walled pulmonary cavitation. A much 
smaller percentage, less than 0.5 per cent 
of white-skinned persons, will develop dis-
seminated coccidioidomycosis following pri-
mary pulmonary inhalation.22 The Negro 
and Filipino are much more susceptible to 
the development of disseminated coccidioi-
domycosis than is the Caucasian.28 When 
dissemination occurs, the spherules are 
spread via the blood stream and lymphatics 
throughout the body. There is no organ 
system which is immune to the develop-
ment of coccidioidomycosis. 
Treatment. No discussion of the therapy 
of coccidioidomycosis would be complete 
without mention of the immunology of the 
disease. Smith29 ,30 has demonstrated very 
conclusively that a rising complement fix-
ing antibody titer very closely parallels dis-
semination of the organism. As the comple-
ment fixing antibody titer rises, it is prob-
able that the coccidioidin skin test sensitiv-
ity will be lost. 
Until amphotericin B became available in 
1956, there was no effective chemothera-
peutic means of treating disseminated coc-
cidioidomycosis. Prior to that time, the aro-
matic diamidines had been given a more 
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than adequate tria}.31-34 They were not ef-
fective in producing the same clinical im-
provement found with their use in North 
American blastomycosis. It must be con-
cluded that they have little or no value in 
the treatment of disseminated coccidioido-
mycosis. The antibiotic, nystatin, <> shows 
in vitro inhibition of Coccidioides immi-
tiS.35-37 This drug, when administered in-
travenously or intramuscularly, causes se-
vere chills, fever, malaise, and emesis to 
such extent that it is no longer in use. The 
oral absorption of nystatin from the gas-
trointestinal tract is so poor that no clinical 
effect can be obtained by the administration 
of the drug via this route. The broad-spec-
trum antibiotics, oxytetracycline, chlortet-
racycline, tetracycline, penicillin, as well as 
the sul£onamides, have not shown any in 
vitro inhibitory effect on Coccidioides im-
mitis.38 The sex hormone, diethylstilbestrol, 
has been reported to show in vitro effect on 
Coccidioides immitis; however, no clinical 
response has been obtained from such ther-
apy.39 Consistently good results have also 
been lacking with testosterone, methyltest-
osterone, and testosterone propionate.4o 
There was evidence that the antibiotic, pro-
toanemonin, would be clinically effective; 
however, this has not been substantiated.41 
Sodium caprylate, ethyl vanillate, fradicin, 
thiolutin, and prodigiosin have been inef-
fective in the treatment of the systemic form 
of the disease.42-44 Many other chemothera-
peutic agents besides those mentioned have 
been tried in this systemic fungus disease. 
They have all been universally ineffective 
in controlling the spread of the causative 
agent, or preventing death from the disease. 
Amphotericin B is the treatment of choice 
for coccidioidomycosis, when therapy is in-
dicated. Indications for treatment include: 
( 1) primary pulmonary coccidioidomyco-
sis in the Negro or Filipino, (2) a residual 
pulmonary cavity, which is increasing in 
size and causing increasing hemoptysis, or 
which has ruptured with spontaneous pneu-
mothorax or empyema, (3) rising comple-
ment fixing antibody titer well beyond the 
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time of the primary pulmonary infection, 
( 4) any clinical evidence of dissemination 
of the disease, (5) any type of surgical 
procedure, particularly corrective pulmon-
ary surgery, (6) pregnancy, since this con-
dition is associated with an increased risk 
of dissemination. The first case report of the 
use of amphotericin B in coccidioidomycosis 
was by Halde, Newcomer, Wright, and 
Sternberg,12 This preliminary report re-
corded a failure from the use of the drug 
administered orally. The second report by 
Fiese45 recorded a favorable response from 
large amounts of amphoteriCin B given 
orally. Klapper, Smith, and Conant46 re-
corded an apparent cure with orally admin-
istered amphotericin B in amounts of 4 Gm. 
per day for lO months, followed by 2 Gm. 
per day for an additional 4 months. Other 
authors47.48 have reported failures following 
the use of amphotericin B given orally. It 
is apparent that the greatest effect from 
this drug is obtained when it is administered 
intravenously. Littman, Horowitz, and 
Swadey6 have reported excellent results 
with the intravenous use of amphotericin B 
in 4 patients with disseminated coccidioido-
mycosis. Other authors48.49 have also re-
ported benefit from this antibiotic when 
given in adequate amounts intravenously. 
It is difficult to understand why the 3 pa-
tients with disseminated coccidioidomycosis 
discussed by Utz, Treger, McCullough, and 
Emmons50 failed to show any response fol-
lowing an adequate intravenous course of 
this drug. It is not likely that these 3 pa-
tients had strains of Coccidioides immitis 
which had become resistant to amphoteri-
cin B. Such resistance has been artifically 
developed in vitro.51 We have had the oc-
casion to treat one patient with coccidioi-
domycosis with intravenous amphotericin 
B. In April, 1957, a 28-year-old white male 
U.S. Army veteran was seen at the Univer-
sity Medical Center in Ann Arbor, Michi-
gan, for an isolated cavity of the right upper 
lung. The patient related that he had been 
aware of the cavity for the 5 years follow-
ing his discharge from the U.S. Armed 
Forces. He had been stationed in the San 
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Joaquin Valley during part of his time in 
the United States Army. One unsuccessful 
attempt at surgical removal of the cavity 
had been performed elsewhere before the 
patient was seen by us. The case was in-
terpreted as one of a solitary, thin-walled 
cavity as the sole remaining evidence of 
previous primary pulmonary coccidioidomy-
cosis. No evidence of dissemination was 
present. Coccidioides immitis was readily 
found on examination of the patient's 
sputum, and positive cultures were ob-
tained on Sabouraud's glucose agar. The 
patient's chief complaint was that of in-
creasing hemoptysis. He did not desire 
further surgery. He was treated with am-
photericin B, administered in a daily dosage 
of 50 mg. dissolved in 1,000 C.c. of 5 per cent 
glucose in water given by slow intravenous 
drip on oonsecutive days for 20 days. He re-
ceived a total dose of 1.0 Gm. of amphoteri-
cin B. By the time the patient had received 
the sixth injection of amphotericin B, his 
sputum became mycologically negative, and 
all evidence of hemoptysis ceased. He 
ceased to raise sputum altogether by the 
time the course of 1.0 Gm. of the drug had 
been given. He developed a mild febrile re-
sponse and nausea with each intravenous 
injection. Prior to the institution of ampho-
tericin B therapy, the cavity measured 3 
cm. in diameter by x-ray examination. One 
year following the amphotericin B therapy, 
the patient had remained completely 
asymptomatic. There was still x-ray evi-
dence of pulmonary cavity; however, it had 
decreased in size to approximately 1 cm. 
in diameter. He has since been lost from 
our observation. This patient had a nega-
tive coccidioidin skin test, and his serum 
was negative for complement fixing anti-
bodies. 
Although a very limited number of pa-
tients have been reported to be treated with 
amphotericin B via the intravenous route, 
there is good evidence that this rather toxic 
antibiotic has a profound in vivo antifungal 
effect. The optimum total dose of ampho-
tericin B remains to be determined. 
Surgical excision of an isolated pulmonary 
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cavity should be considered if the cavity 
cannot be closed by amphotericin B therapy 
or by pneumothorax or pneumoperitoneum. 
Complications accompanying pulmonary 
operation for coccidioidal cavities have 
been few, but relatively serious. Any surgi-
cal procedure performed on a patient with 
coccidioidomycosis should be accompanied 
by amphotericin B therapy. 
Histoplasmosis 
Numerous epidemiologic studies and his-
toplasmin skin test surveys have radically 
changed the old ooncept of histoplasmosis 
as being a rare and fatal disease. It is now 
known on all continents, with the highest 
reported endemicity in the East Central 
states of the United States bordering the 
tributaries of the Ohio, Missouri, and Mis-
sissippi rivers.52,53 In these endemic areas, 
the incidence of histoplasmin reactors may 
reach the figures of 80 to 90 per cent of the 
population. 
The disease is caused by Histoplasma 
capsulatum, which is dimorphic like Blas-
tomyces dermatitidis, Blastomyces brasili-
ensis, and Sporotrichum schenckii. The tis-
sue forms are small, 1 to 5 fA in size, round or 
oval, yeastlike budding organisms, predom-
inantly located in reticuloendothelial cells. 
The saprophytic phase is mycelial, produc-
ing characteristic tuberculate chlamydo-
spores which are considered as the infective 
structure of the organism in natural ex-
posures. The reservoir in nature is the soil, 
as indicated by repeated isolation of the 
organism from soil samples-particularly 
those associated with chicken and bat drop-
pings from endemic areas and from point 
sources of reported epidemics.54 Evidence 
points to histoplasmosis as being an air-
borne infection, with the respiratory tract 
as the major portal of entry. Under normal 
conditions of exposure the infection may be 
so mild as to be asymptomatic; or, if symp-
tomatic, after an incubation period of 5 
to 15 days, it may appear as an inHuenza-
like or respiratory condition, usually mis-
taken for a common cold, tuberculosis, 
bronchopneumonia, or other nonmycotic 
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ailments. The x-ray findings are hilar ad-
enopathy and/or parenchymal infiltrates. 
Precipitins and complement fixing anti-
bodies appear, and the histoplasmin skin 
test becomes positive. As a rule, the patient 
recovers after a few weeks, although the 
pulmonary lesions may persist and eventu-
ally beoome calcified. Not more than 1 per 
cent of the primary infections progress to 
the disseminated, fatal form, although re-
cently more and more cases of the chronic 
progressive pulmonary type of histoplas-
mosis (which closely resembles chronic fi-
brocaseous pulmonary tuberculosis) are be-
ing recognized, particularly in tuberculosis 
sanatoria.5G The disseminated form with 
fever, weakness, anemia, wasting, and hepa-
tosplenomegaly is the classical clinical pic-
ture by which histoplasmosis was previ-
ously known. 
Histoplasmosis is generally regarded as 
a protean disease running the gamut of 
symptomatology from a mild, almost sub-
clinical upper respiratory infection to an 
overwhelming, fatal septicemia, with the 
clinical picture related to the sites involved. 
Furcolow56 described the following clinical 
types: 
1. Severe 
a. chronic progressive (reinfection or 
cavitary) 
b. acute progressive 
c. acute epidemic 
2. Moderately severe 
3. Mild 
4. Asymptomatic 
The significance of immunologic phenom-
ena in histoplasmosis parallels that in coc-
cidioidomycosis and North American blas-
tomycosis.57 Precipitins and complement fix-
ing antibodies become measurable during 
the early stage of the infection. They disap-
pear as the illness subsides, thus indicating 
the severity and extent of the disease proc-
ess. The skin hypersensitivity, as demon-
strated by the histoplasmin skin test, de-
velops from 4 to 6 weeks after the onset 
of the disease and persists for many years. 
Its significance is similar to that of the tu-
berculin test, indicating a past or present 
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infection. It may be used as a measure of 
resistance of the body to the infection. The 
complement fixation test and the histoplas-
min skin test are interpreted together for 
diagnostic and prognostic purposes and are 
valuable tools in the evaluation of the ef-
fectiveness of the treatment instituted. 
Treatment. The extreme variation in the 
clinical picture and course of histoplasmosis 
makes the evaluation .of therapeutic modali-
ties difficult. Immunologic mechanisms ap-
parently play a significant role and should 
be considered in the response of the patient 
to therapy, which varies markedly depend-
ing upon the severity and clinical type of 
the infection. This becomes important in 
the absence of an effective etiological treat-
ment. 
The acute primary pulmonary infection 
is generally benign and self-limited, thus 
nonspecific supportive and symptomatic 
measures suffice. Many patients do not even 
seek medical assistance. However, this type 
of case may occasionally become severe 
enough to threaten the life .of the patient 
as may occur in the acute epidemic form 
with unduly massive exposure to the infec-
tive organism.58 The question of the use of 
steroids in these cases has been raised in 
spite of their known association with dan-
gerous spread of infectious processes. Al-
though Baum, Adriano, and Schwarz59 
failed to observe any influence of cortisone 
on the dissemination of experimental histo-
plasmosis, others60-62 obtained evidence of 
wider spread. In clinical trials, certain au-
thors noted an association of the spread of 
the infection with administration of ster-
oids,63-65 while others thought that the ster-
oids contributed to the clinical improvement 
and the clearing of lesions.66-68 A special in-
dication for the use of steroids in histoplas-
mosis has been pointed out by Schwartz69 
and Packard, Finkelstein, and Turner.70 
Carefully controlled administration of ster-
oids may even prove lifesaving by virtue 
of their anti-inflammatory and antitoxemic 
effects in patients threatened by a self-
limited but massive acute pulmonary infec-
tion with severe toxemia and high fever. 
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The drugs, however, should not be given 
during the first 2 weeks of illness when the 
body has not yet had the chance to build 
up adequate immunologic defense. The 
risk of dissemination may be minimized by 
the concomitant administration of one of 
the more successful histoplasmostatic agents 
as was done by Tegeris and Smith,68 who 
used cortisone and MRD-1l2. The use of 
amphotericin B as an antifungal "cover" 
may be more promising. 
The problems enoountered in the man-
agement of chronic pulmonary histoplas-
mosis are similar to those in chronic pul-
monary tuberculosis.55 The indications for 
sanatorial treatment, supportive and symp-
tomatic measures, and surgical intervention 
are similar, except for the lack of an ac-
cepted specific drug in histoplasmosis. Sur-
gical excision of localized lesions has proved 
of definite value.71-74 
The almost uniformly fatal course of pro-
gressive disseminated histoplasmosis high-
lights the need for an effective specific 
drug. The newer drugs that have shown a 
certain measure of success are ethyl vanil-
late, ,8-diethylaminoethyl fencholate 
( MRD-1l2), and sulfadiazine, but they are 
being discarded in favor of the more effec-
tive amphotericin B. The aromatic diami-
dines and nystatin are generally considered 
ineffectual in clinical trials. 
Ethyl vanillate (ethyl-4-hydroxy-3-meth-
oxybenzoate) was first used clinically in 
1951 by Christie, Middleton, Peterson, and 
McVickar75 on 12 children with dissemi-
nated histoplasmosis. Five recovered. Sub-
sequent trials by other authors76-84 gave 
variable results. The drug is administered 
orally in large doses up to 40 Gm. It causes 
distressing gastrointestinal irritation and 
serious toxic reactions, with a narrow mar-
gin of safety between the toxic and the 
therapeutic doses. These are distinct dis-
advantages, especially with the introduction 
of other drugs, equally effective but less 
toxic. 
Ludwig, Murray, Smith, Thompson, and 
Werner85 demonstrated the in vitro anti-
fungal activity of MRD-1l2 at a concentra-
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tion of 0.1 mg. per milliliter of medium. As 
with ethyl vanillate, the therapeutic results 
in humans with the use of MRD-1l2 have 
been inconsistent.66,84,869l The drug is given 
f.or 1 to 2 months in daily doses of 150 to 
600 mg. as a slow intravenous drip. Except 
for some evidence of hepatic degeneration, 
it has not shown serious toxicity. 
The results of laboratory studies on the 
in vitro and in viv.o antifungal activity of 
the sulfonamides on Histoplasma capsula-
tum have been contradictory, although the 
recent reports of Mayer, Eisman, Geftic, 
Konopka, and Tanzola92 and Louria and 
Feder93 agreed on their effectiveness in 
protecting mice against experimental histo-
plasmosis. The clinical use of sulfonamides 
in human histoplasmosis has generally been 
regarded as disappointing. There are, how-
ever, reports of favorable results, and, re-
cently, Christie94 has reinvestigated the 
problem by treating 3 cases of progressive 
disseminated histoplasmosis and 2 cases of 
the ulceroglandular type with sulfonamides. 
All five achieved clinical remission. It is to 
be noted that Latin-American authors have 
taken exception to the general opinion that 
sulfonamides are ineffective in histoplas-
mosis. Their successful experience in im-
proving the prognosis of South American 
blastomyoosis with the use of sulfonamides 
has led to their use of these drugs in cases 
of histoplasmosis, resulting in more satis-
factory clinical responses and a number of 
apparent clinical cures through the admin-
istration of large doses for prol.onged peri-
OdS.95-l0l Corder098 felt that most of the re-
ported clinical failures were due to rela-
tively small doses or short periods .of ad-
ministration. As in South American blas-
tomycosis, the sulfonamide preparations, 
particularly sulfadiazine, are given orally in 
daily doses of 3 to 6 Gm. for months. 
The best therapeutic results s.o far have 
been obtained with the use of amphotericin 
B. The number of cases reported is still 
relatively small, and the periods of post-
treatment observation still too short for 
exact evaluation of its value; but the pre-
liminary findings are certainly promising. 
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The inhibitory in vitro concentration of the 
drug against Histoplasma capsula tum is 
very low, as little as 0.04 p.g per milliliter 
of medium.I,3,13,I02 The drug is highly pro-
tective in experimental histoplasmosis in 
animals.2,19,20,103 Amphotericin B has been 
tried on at least 34 cases of human his to-
plasmosisy,16,2o,50,91,I04.110 Two pa tien ts 
with acute pulmonary histoplasmosis im-
proved. Although the fall in temperature 
and the rapid resolution of the infiltrates 
coincided with the institution of therapy 
with amphotericin B, the claim of improve-
ment is at most suggestive in view of the 
good prognosis of this form .of histoplas-
mosis. Nine cases of the chronic pulmonary 
type were treated. The symptoms were ar-
rested in one, improved in 7, and no change 
appeared in one case with oral administra-
tion of 2.0 to 4.0 Gm. of the drug daily for 
40 days. Eighteen cases .of progressive dis-
seminated histoplasmosis were treated. 
Seven clinical remissions were observed, 
with follow-up periods ranging up to 18 
months. Nine patients improved dramatic-
ally. One also showed improvement with 
oral treatment, but died in 7 months. Three 
other deaths occurred, but the drug was 
administered only a few times during the 
terminal stages of the disease. Certainly 
these figures are unparalleled. 
North American blastomycosis 
North American blostomycosis is caused 
by the fungus, Blastomyces dermatitidis, 
an organism which grows readily on Sabou-
raud's glucose agar at room temperature as 
a filamentous mold, and on blood agar at 
37° C. as a yeastlike fungus. The tissue 
phase of the fungus appears as a character-
istic single-budding structure of 5 to 15 p. 
in diameter, and exhibits a refractile cell 
wall from which the protoplasm has often 
'shrunk away, giving a double-contoured ap-
pearance. The polysaccharide wall of the 
organism is well demonstrated in tissue by 
means of the periodic acid-Schiff stain. The 
diagnosis of North American blastomycosis 
can be established by cultures or by the 
finding of the causative agent on direct 
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microscopic examination of pus obtained 
from the cutane.ous lesions or from other in-
fected clinical material. 
North American blastomycosis is most 
frequently encountered in the Southern, 
Southeastern, and Midwestern areas of the 
United States. Cases of the disease have 
been reported sporadically from other geo-
graphic areas of the United States as well as 
Canada. III There is doubt that the disease 
has been acquired outside of the North 
American continent, even though case re-
ports from other continents are in the medi-
cal literature. Blastomyces dermatitidis has 
not, as yet, been isolated from the soil in 
which it must logically exist.112 The organ-
ism shows a decided tendency to produce 
disease in the male sex. Reported ratios of 
men to women average approximately ten 
to one.1l3·115 The disease has now been re-
ported in siblings1l2 and develops in all age 
groups. One small epidemic of North Ameri-
can blastomycosis has recently been re-
portedY2 
North American blastomycosis is nearly 
always acquired by inhalation of the causa-
tive fungus. This somewhat revolutionary 
thought was first advanced by Schwarz and 
Baum,1l6 and it has been slow to be gen-
erally accepted. The rare person who has 
had known primary cutaneous inoculation 
blastomycosis has followed a clinical pat-
tern resembling that of primary inoculation 
tuberculosis or sporotrichosisY7,118 There 
has been no instance recorded of known pri-
mary inoculation blastomycosis developing 
into a systemic blastomycosis. There is now 
evidence that a subclinical form of pulmon-
ary blastomycosis occurs, similar to that en-
countered in coccidioidomycosis and histo-
plasmosisY2,113,115 The blastomycetes are 
disseminated from the lungs via the blood 
stream and lymphatics to other organs of 
the body, with a predilection for the skin, 
subcutaneous tissue, and bone. Pulmonary 
blastomycosis mimics most of the other deep 
mycoses, as well as tuberculosis, while the 
cutaneous granulomas also closely simulate 
tuberculosis, tertiary syphilis, other deep 
mycoses, and certain drug eruptions. 
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Treatment. The therapy of North Ameri-
can blastomycosis should not be discussed 
without emphasis, first, upon the impor-
tance of correlating the results of therapy 
with the immunologic status of the patient. 
Smith1l9 was the first to recognize that the 
prognosis of a patient with blastomycosis is 
dependent to a large extent upon the im-
munologic response of the individual. The 
prognosis is best in patients who have a 
positive blastomycin skin test and no de-
monstrable complement fixing serum anti-
bodies. Spontaneous cure has been re-
ported1l2 in a patient who exhibited this 
immunologic pattern. The prognosis is poor-
est in those patients who have a negative 
blastomycin skin test and a high titer of 
complement fixing serum antibodies. 
2-Hydroxystilbamidine and amphotericin 
B, both administered intravenously, repre-
sent the two present choices for chemo-
therapy of North American blastomycosis. 
Evidence is accumulating that amphotericin 
B will prove to be superior to 2-hydroxystil-
bamidine. The use of 2-hydroxystilbamidine 
in generalized North American blastomyco-
sis was first reported by Snapper, Schneid, 
McVay, and Lieben.120 This aromatic di-
amidine does not cause the toxic neurologi-
cal effect which was almost universally re-
corded with stilbamidine when the latter 
drug was given in doses greater than 1 
Gm.120-125 Very excellent reviews have 
been reported on the aromatic diami-
din e s .120,126.127 2-H ydroxystilbamidine has 
gained widespread acceptance in the ther-
apy of North American blastomycosis.38,115, 
128 This drug is supplied in vials of 225 mg. 
The dose of 450 mg. of the drug is as well 
tolerated as is the smaller 225 mg. dose. 
This amount of 2-hydroxystilbamidine is 
dissolved in 500 to 1,000 C.c. of 5 per cent 
dextrose solution or isotonic saline and ad-
ministered intravenously by slow drip. The 
solution is made up each day, just prior 
to its administration. Care should be taken 
to keep the drug from direct sunlight, since 
it has been well documented that toxicity 
of the compound increases upon exposure 
to direct sunlight. The drug is administered 
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on consecutive days, although rest periods 
of days to weeks may safely be given. A 
course of 9.0 Gm. of 2-hydroxystilbamidine 
represents an adequate course of the drug. 
Healing of the cutaneous lesions and symp-
tomatic improvement are usually noted by 
the end of the second week of therapy. 
Complete healing has usually taken place 
by the end of the first month following the 
cessation of therapy. 2-Hydroxystilbamidine 
is deposited in various organs, especially 
the liver, kidneys, adrenals, sweat glands, 
and skin,12o,127 and continued improvement 
occurs for at least several weeks following 
the last administration of the drug. 
There are reports documenting relapse 
of North American blastomycosis following 
adequate amounts of aromatic diamidine 
therapy.129-131 Most of these recurrences 
have been in individuals who have contrib-
uted little to their own immunologic de-
fense, as evidenced by negative blastomy-
cin skin tests and positive complement fix-
ing antibody tests. There is also evidence 
that resistance to 2-hydroxystilbamidine is 
developed by specific strains of Blastomyces 
dermatitidis .132 
Intravenous amphotericin B therapy has 
proved effective in 8 cases of North Ameri-
can blastomyoosis treated at the University 
of Michigan Medical Center.l18 Five of 
these successes ocourred in patients who 
had exhibited repeated relapses following 
massive amounts of aromatic diamidine 
therapy.n8 Utz, Treger, McCullough, and 
Emmons50 have reported 4 cases of sys-
temic North American blastomyoosis treated 
with intravenous amphotericin B. One of 
these 4 patients received only no mg. total 
amount of the drug. This does not represent 
an adequate amount of therapy. The other 
3 received between 2.2 and 5.1 Cm. of am-
photericin B in daily amounts varying be-
tween 30 and 45 mg. per dose. This aver-
aged between 0.5 and 0.6 mg. per kilogram 
of body weight. These 3 patients are re-
ported to have made apparent recovery, al-
though an adequate follow-up time has not 
yet elapsed to evaluate these results thor-
oughly. Toxic symptoms in the form of 
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nausea, vomiting, marked anorexia, chills, 
and fever were reported in the same pa-
tients. Nevertheless, these authors conclude 
that amphotericin B is the drug of choice 
for disseminated North American blastomy-
cosis. 
Five of the 8 patients reported upon by 
us received but 1.0 Cm. of amphotericin B 
as a total dose. All 5 of these patients have 
apparently been cured, with a follow-up 
time varying from 11 to 29 months. Three 
of our 8 patients have had a relapse fol-
lowing amphotericin B therapy. One of 
these 3 was the first patient we treated 
with this antibiotic, and in retrospect we 
realize that he had received an inadequate 
amount of the drug when first treated. He 
was then given 1.0 Cm. of the drug, bring-
ing his total dose to 1.5 Cm. He is ap-
parently cured at the present time, being 26 
months post treatment. The 2 other patients 
who suffered a relapse have received 4.0 
and 4.5 Cm. of amphotericin B, respec-
tively. These 2 patients had had wide-
spread disease for many years pri.or to 
amphotericin B therapy. Each course of re-
treatment with this antibiotic has proved 
to be effective in producing temporary ces-
sation of all signs and symptoms of active 
disease. These two patients are currently 
14 and 15 months post treatment with.out 
evidence of active infection. It appears to 
us that a smaller total dosage of amphoteri-
cin B is required in the treatment of North 
American blastomycosis than is required in 
the therapy of any of the other systemic 
myc.oses. The dosage of 50 mg. of ampho-
tericin B given by slow intravenous drip, 
with the concomitant use of judicious 
amounts of steroid hormones and chlor-
promazine at intervals of every other day, 
to a t.otal dose of 1.0 Cm., represents the 
most effective means at hand of curing 
North American blastomycosis. 
The oral form of amphotericin B is poorly 
absorbed, and, in spite of the one case133 re-
porting benefit from such oral administra-
tion, we do not feel that this form of ampho-
tericin B therapy should be given further 
trial. 
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Prior to the use of the aromatic diamidine 
and amphotericin B, a number of drugs had 
been tried for this disease. None .of them 
have proved consistently effective. A satu-
rated solution of potassium iodide adminis-
tered orally and in increasing amounts had 
proved the only form of therapy which 
promised any beneficial effect. The cures 
which have been rep.orted from the use of 
iodides usually ocourred in individuals with 
the immunologic status of a positive blas-
tomycin skin test and no complement fixing 
serum antibodies. More recently, Corn-
bleet134 has advocated the use of a solution 
.of potassium iodide plus thyroid extract in 
the treatment of North American blastomy-
cosis. The 9 patients included in his report 
responded impressively to this form of ther-
apy. There have been no follow-up or cor-
roborative studies reported. There is doubt 
that there is any remaining place for iodide 
therapy or any of the older means of ther-
apy advocated prior to the introduction of 
2-hydroxystilbamidine. 
South American blastomycosis 
South American blast.omycosis has been 
reported almost exclusively from South 
America, especially from Brazil. With in-
creased opportunities for travel and greater 
population movements, however, cases may 
be encountered in countries distant from 
the known endemic areas, as exemplified 
by occasional reports from Cermany,135 
Italy,136 and the United States.137,138 
The causative organism, Blastomyces 
brasiliensis, is a dimorphic fungus with fila-
mentous growth at room temperature and 
yeastlike morphology at 37° C. The organ-
ism is characterized by multiple budding. 
Even though it has n.ot been isolated yet 
from soil or plants, evidence points to a 
saprophytic phase in nature. The portal of 
entry is mainly the muc.ous membranes of 
the mouth, pharynx, or respiratory tract, ac-
counting for the prep.onderant occurrence 
of the granulomatous lesions in these areas. 
From these locations, the infection dissemi-
nates through the blood stream and the 
lymphatic system to affect any organ, caus-
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ing grave septicemic lesions. The lymph 
nodes and gastrointestinal tract are com-
monly involved. Lacaz139 described the fol-
lowing anatomoclinical forms: (1) muco-
cutaneous, (2) ganglionary (lymphatic), 
( 3) visceral, (4) mixed, and (5) blastomy-
cosis associated with neoplasms and other 
infectious diseases. 
Experience with the parac.occidioidin skin 
test and complement fixation test in South 
American blastomycosis is as yet limited 
and the results inconsistent.57 Better stand-
ardization and more studies may yet prove 
these procedures as valuable in the diag-
nosis and prognostication of South Ameri-
can blast.omycosis as of coccidioidomycosis, 
histoplasmosis, and North American blasto-
mycosis. 
Treatment. The prognosis of South Amer-
ican blastomycosis is generally grave. In 
some cases death may occur in 6 months, 
but the usual patient suffers through 2 to 4 
years. The use .of iodides, arsenicals, bis-
muth, gold, antimony, and certain dyes, like 
malachite green and methylene blue, had 
not modified significantly the serious course 
of the disease. However, since Ribeiro first 
treated a group of patients with sulfona-
mides in 1940 and obtained favorable re-
sults, the prognosis in this disease has been 
greatly impr.oved. The response to sulfon-
amide therapy is satisfactory and the life 
expectancy of the patient is increased. Even 
biologic cures, though relatively few, have 
been claimed. To attain these, the adminis-
tration of the drug must be early, intensive, 
and prolonged. Any of the sulfonamide 
preparations may be used singly or in com-
bination. Sulfamerazine, Gantrisin, and, es-
pecially, sulfadiazine are preferred. The 
daily .oral dose is 1 to 2 Gm. every 4 to 6 
hours. In this way the effective blood level 
of 10 to 15 mg. per 100 m!. is attained and 
must be maintained continuously for long 
periods of time, even after apparent clini-
cal cure. Relapses are common, particularly 
when administration of the drug is sus-
pended. The recurrences are resistant to 
the resumption of therapy. The protracted 
administration of such large doses of sul-
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fonamides that the total dose may reach 
even a few thousand grams entails the risk 
of toxicity. Periodic examinations for such 
toxic effects should be made. 
In spite of the notable improvements at-
tained with sulfonamides, the relapses, the 
toxicity of or intolerance to the drugs, the 
few actual mycologic cures, and the pro-
tracted therapy comprise the incentive to 
search for better agents. The antibacterial 
antibiotics are ineffective, as are ethyl va-
nillate140 and nystatin.141 Floch and Sac-
charin 142 claimed a clinical cure with 4,4'-
diaminodiphenyl sulf.one (DDS). 
The hope that the favorable therapeutic 
effect of stilbamidine or 2-hydroxystilbam-
idine on North American blastomycosis 
would be of the same magnitude, if not 
greater, on South American blastomycosis 
has not been fulfilled. Blastomyces brasili-
ensis clinically has proved much less sen-
sitive.138,143,144 Another aromatic diamidine, 
diamidinodiphenylamine (M & B 938), 
proved to be more promising, however. 
MacKinnon, Sanjines, and Artagaveytia-AI-
lende144 tested six strains of Blastomyces 
brasiliensis and found the inhibitory con-
centration at 2 to 5 mcg. per milliliter of 
medium. They observed healing of oropha-
ryngeal lesions and marked improvement 
of lung changes in a patient given two 
courses .of daily intravenous injections of 
150 mg. of M & B 938 with a total of 4 Gm. 
Another patient also showed definite im-
provement with a total of 5.475 Gm. in 43 
days. There was no serious toxic reaction.145 
In their initial studies of the in vitro anti-
fungal spectrum of amphotericin B, Gold, 
Stout, Pagano, and Donovick and Sternberg, 
Wright, and Oura included Blastomyces 
brasiliensis which turned out to be sensitive. 
On the strength of these findings, Lacaz 
and Sampaio146 treated 4 cases of South 
American blastomycosis with amphotericin 
B. The clinical results they obtained were 
so pr.omising as to prompt them to state that 
a new era in the treatment of South Ameri-
can blastomycosis had opened with ampho-
tericin B. Although kept alive by sulfona-
mide therapy, all 4 patients were essentially 
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refractive to the drug. One patient had 
taken more than 10,000 Gm. of sulfona-
mides in the course of 19 years, and an-
other, 7,500 Gm. in 10 years. The relapses in 
each patient were controlled by amphoteri-
cin B with healing of the lesions, but no 
cure could be claimed, for the follow-up 
periods were still too brief. 
Cryptococcosis 
The true incidence of cryptococcosis is 
probably much higher than is indicated by 
the case reports in the literature of the 
severe pulmonary and meningoencephalitic 
forms with which most clinicians associate 
the disease. In the absence of a high index 
of suspicion and effective skin testing and 
serologic procedures, many of the benign, 
localized forms of cryptococcosis that simu-
late more commonly known diseases may 
go on to healing without being diagnosed. 
The condition has been reported from many 
oountries and in both sexes and all ages. 
The culturally and morphologically yeast-
like organism, Cryptococcus neoformans, 
causes the disease. It is unique among the 
pathogenic fungi in the mucoid character of 
its colonies and the wide capsule surround-
ing its yeastlike body. The organism has 
been isolated from the skin and gastro-
intestinal tract of normal individuals, but 
more frequently from soil samples, espe-
cially those associated with pigeon and 
chicken droppings,147,148 The infection may 
be endogenous, but probably more com-
monly results from an exogenous source 
through the respiratory tract and, occasion-
ally, through the skin or gastrointestinal 
tract. 
Because the vast majority of reported 
cases of cryptococcosis showed marked in-
volvement of the central nervous system, 
the disease has become popularly associated 
with this particular form. In accord with 
the suspected mode of entrance of the or-
ganism through the respiratory tract, how-
ever, more and more attention has been di-
rected to the pulmonary form of the dis-
ease. In many cases pulmonary complaints 
were registered at one time or another dur-
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ing the oourse of the illness. Although pri-
mary pulmonary cryptococcosis may at 
times cause death in a short time, the in-
fection generally runs a benign, even sub-
clinical, course with localized lesions that 
may resolve with or without minimal scar-
ring. Eight of the 10 cases of pulmonary 
cryptoooccosis described by Jacobs149 re-
vealed a solitary granulomatous nodule. 
These primary lesions in the lungs, whether 
active or healed, are frequently discovered 
only at autopsy on patients who die of the 
disseminated or meningitic form. The signs 
and symptoms of pulmonary cryptococcosis 
are those of chronic pneumonitis, lung 
tumor, or lung abscess. 
With no regard to the course taken by the 
primary pulmonary condition, the infection 
may be disseminated hematogenously to 
other organs, with a predilection for the 
central nervous system. When this happens, 
the clinical picture becomes dominated by 
the central nervous system involvement, 
with signs and symptoms of meningeal ir-
ritation or increased intracranial pressure 
frequently misdiagnosed as tuberculous 
meningitis, brain tumor, brain abscess, or 
sub arachnoidal hemorrhage. Involution of 
the pulmonary lesions may continue even in 
the face of this dissemination. Cryptococco-
sis of the central nervous system is almost 
always progressive, generally causing death 
in 3 to 4 months, sometimes in one year or 
so. However, unexplained remissions do 
occur and the patient may live up to 16 
years, as in Beeson's150 case. 
Treatment. There is as yet no generally 
accepted effective treatment of disseminated 
cryptococcosis. Evans and Harrell151 found 
that at least 43 methods, including the 
usual antibiotics, sulfonamides, x-rays, fever 
therapy, alkalinization, gold, copper, arseni-
cals, iodides, and vaccines, had been used. 
All proved essentially ineffectual. Except 
for amphotericin B, even the newer anti-
fungal antibiotics and chemotherapeutic 
agents effective in vitro and in other my-
cotic infections give variable results, which 
suggests that possibly the apparent cures 
claimed for these drugs were actually spon-
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taneous remissions. The observed resistance 
of Cryptococcus neoformans to drug ther-
apy has been related to the thick capsule 
surrounding the organism. 
Because of their in vitro activityl52,l53 and 
demonstrated usefulness in the treatment of 
North American blastomyoosis, the aromatic 
diamidines have been tried on clinical cases 
of cryptococcosis, in spite of failures in 
protecting laboratory animals against ex-
perimental infections.154-l56 Leithold, 
Reeder, and Bakerl57 and Whitehill and 
Rawsonl58 claimed apparent cure with 2-
hydroxystilbamidine in one case each, and 
Fergusonl59 achieved marked improvement 
in another. The use of stilbamidine or pro-
pamidine, however, has been associated 
with clinical failure.l59-l63 
Nystatin has been found active in vi-
trol64,165 and in animal experiments.35,l56,166 
However, unlike its signal success in candi-
diasis, the few trials in human cryptococcic 
infections have thus far essentially failed to 
confirm such activity.167-l71 Perruchio, 
Bruel, Lagarde, and Delpy172 used sulfadi-
azine and nystatin to treat a residual pul-
monary lesion after resection in a 12-year-
old girl. The sulfadiazine had to be stopped 
because of digestive intolerance but nystatin 
was administered for 20 days without 
trouble. The pulmonary lesion remained 
stationary. 
Cycloheximide (actidione) is an antifun-
gal antibiotic that has a selective marked 
in vitro activity against Cryptococcus neo-
formans among the pathogenic fungi,35,164, 
173 It is not active, however, in experimental 
infections.174 Likewise, in clinical trials only 
an occasional patient responded favor-
ably.li5-l78 The majority were not influenced 
and, in one instance, the drug might have 
even brought on an acute exacerbation of 
the disease and caused death.167,179-l85 The 
antibiotic is given intravenously, intrathec-
ally, and/or intramuscularly. The initial 
dose is 20 mg., increased daily up to 100 to 
200 mg. The intrathecal dose is 10 to 20 mg. 
The treatment is prolonged. Except for 
nausea and vomiting that may be severe, 
no serious toxicity has been observed. 
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In contrast with the other drugs, ampho-
tericin B has exhibited a most encouraging 
activity. So far it is the most effective drug 
in the treatment of cryptococcosis and is 
apparently changing the gloomy outlook in 
this grave disease. It inhibits the organism 
in vitro at very low concentrations, down 
to a fraction of a microgram per milliliter of 
medium.l ,13,102 The increasing clinical use 
has consistently produced favorable results 
hitherto unknown in the management of 
cryptococcosis. Thus far, at least 49 patients, 
the majority of whom had central nervous 
system involvement, have been reported 
treated with amphotericin B.n,16,50,9l,llO,168, 
171,186-197 Apparent clinical remissions were 
claimed in 17 cases with follow-up periods 
of from 4 to 18 months. Nineteen improved 
in varying degrees, with 8 noted as having 
attained oonversion of the cultures for the 
organism to negative. Three patients were 
reported unimproved, but in 2 of them the 
drug was administered mainly by the oral 
route. Two relapses and 8 deaths occurred, 
but in 6 cases medication was instituted late 
in the course of the disease a short time be-
fore death, and the authors expressed the 
opinion in each case that the treatment was 
not given a fair trial. In one case the or-
ganism disappeared from the spinal fluid, 
and death was blamed on bacteremia and 
renal failure. 
Surgical intervention has a definite place 
in the management of cryptococcosis, being 
particularly indicated for excision of early, 
localized lesions before dissemination oc-
curs,198-202 The resection of primary lesions 
has been attempted even in the presence 
of spread to the central nervous system in 
the hope of preventing further seeding from 
these primary foci. 
Actinomycosis 
Actinomycosis is a subacute to chronic 
suppurative granulomatous disease charac-
terized by brawny inflammatory lesions, ab-
scess formation, and multiple draining si-
nuses and fistulas. It is world-wide in dis-
tribution with no racial predilection and 
affects all ages, especially young adults. 
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The single causative organism is Actino-
myces israeli (syn. Actinomyces bovis) 
which is gram positive, non-acid fast, 
branching, filamentous, and anaerobic. The 
diagnostic "sulfur granules" found in the 
exudate from the abscesses or draining le-
si.ons are dense networks of the filamentous 
organism radially arranged, with clublike 
endings. 
Actinomyces israeli has been isolated 
from the gums, periodontal pockets, and 
peritonsillar crypts of normal individuals. 
The infection is apparently endogenous, 
with trauma or disease as c.ontributory fac-
tors related to lowered local tissue resist-
ance and acquired pathogenicity of the or-
ganism. "Mixed infection" with other sym-
biotic bacteria, as Actinobacillus actinomy-
cetem-comitans, Bacterium melaninogeni-
cum, and anaerobic streptococci has been 
implicated as part of a pathogenic complex 
with Actinomyces israeli.203-206 
A wide variety of signs and symptoms is 
observed in actinomycosis depending upon 
the part of the body invaded. The three 
main clinical types are (1) cerVicofacial, 
comprising more than half of the reported 
cases, (2) abdominal, 20 per cent, and (3) 
thoracic, 15 per cent. The rest of the cases 
present involvement of other parts of the 
body such as the extremities, liver, genitals, 
kidneys, skin, bones, joints, or central ner-
vous system. Spread of the infecti.on is by 
direct invasion. The prognosis of cervic.o-
facial actinomycosis is generally much bet-
ter than that of the abdominal or thoracic 
types. 
Treatment. Before the advent of sulf.ona-
mides and penicillin in the treatment of ac-
tinomycosis, a multitude of therapeutic 
measures (including iodides, x-rays, surgi-
cal procedures, vaccines, copper salts, thy-
mol, gold, arsenicals, and others) were uti-
lized with varying results. Singly, they were 
ineffective, especially in the abdominal and 
thoracic forms of the disease. Even in oam-
bination, mast .of the reparts .of their favar-
able use were an cases .of cervicafacial ac-
tinomycasis which has a relatively fair prog-
nasis, even without therapy. Many .of these 
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alder methods have been discarded except 
far a few, such as iadides and x-rays, which 
are retained by same as helpful adjunctive 
measures ta penicillin treatment. 
Althaugh later praved ta be less effective 
than penicillin and the ather antibiatics in 
vitr0207,208 and in clinical treatment,209-211 
the sulfonamides gave the first cansistent 
favorable results in the treatment of actina-
mycasis and impraved the pragnasis of the 
disease during the years fallawing its in-
troductian in 1937. Better results were 
achieved when these drugs were cambined 
with adjunctive treatment, such as surgical 
interventian, iadides, or x-rays. Of the sul-
fanamides, sulfadiazine and sulfisaxas.ole 
are the better preparations.212 Oral dases 
.of 3 ta 4 Gm. daily with effective bload 
levels .of 8 ta 10 mg. per 100 ml. shauld be 
maintained thraugh a periad of 4 ta 6 
months or longer. The usual precautians 
against possible taxicity must be .observed. 
Penicillin was introduced in 1945 and has 
steadily supplanted the sulfonamides. The 
actinamycete is mast sensitive ta penicillin 
in vitra,213-215 and a hast of successful clini-
cal rep arts testify to the superiar efficacy .of 
penicillin. Althaugh in many .of these re-
parts penicillin was combined with ather 
therapeutic measures, the antibiatic unques-
tianably has augmented the rate .of recav-
ery, especially in the graver abdominal and 
tharacic forms. There are still treatment 
failures, hawever, in spite of the demon-
strated sensitivity .of the .organism to the 
antibiatic. The very nature .of the disease 
process with its excessive formatian .of gran-
ulamatous and fibraus tissues impedes the 
effective concentratian of the drug in the 
diseased area. This necessitates the admin-
istratian of large dases far pralanged peri-
ads and the aid afforded by adjunctive ther-
apy, such as surgical measures and iadides. 
Anather suggested reason far these treat-
ment failures is the penicillin resistances of 
certain bacteria like Actinobacillus actino-
mycetem-comitans camprising part .of the 
symbiatic flara respansible for the cancom-
itant infection in actinomycosis. 
The recammended average dase of peni-
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cillin is 3 to 6 million units daily for at least 
3 months, extending even to 12 to 18 
months, depending upon the response of the 
patient. 
The need for another effective drug that 
can be used in place of penicillin has beelJ 
felt for several reasons: (1) the cases that 
appear to be resistant to penicillin treat-
ment, (2) the increasing incidence of sensi-
tization to penicillin, and (3) the objections 
to repeated parenteral injections over long 
periods of time. The newer broad spectrum 
antihiotics and other chemotherapeutic 
drugs have been investigated and success-
fully used. They include streptomycin, 
tetracycline, oxytetracycline, chlortetra-
cycline, e r y t h rom y c in, chloramphenicol, 
isoniazid, and stilbamidine. It is still quite 
early to confirm the exact value of these 
drugs. Erythromycin, at least in vitro, is the 
most effective. Their main disadvantages, 
especially those of the broad-spectrum anti-
biotics, are their toxicity and their high cost 
as compared with penicillin. 
Surgical measures are generally admitted 
to be of considerable value, if not curativ~ 
as in localized lesions. The procedures 
range from simple aspiration of fluid to rad-
ical complcte excision of diseased organs, as 
pneumonectomy, nephrectomy, or resection 
of intestines. Better results are 0 b t a i ned 
when these are associated with drug ther-
apy. 
Only a small number of reported cases of 
actinomycosis were managed with a single 
mode of therapy. Most were given multiple 
treatments with preference for penicillin, 
combined with sulfonamides or anyone of 
the other antibiotics and chemotherapeutic 
drugs, iodides, x-rays, and surgical proce-
dures. Because of strain variation:!07,2H,216 
the desirahility of sensitivity tests per-
formed on the actinomycetes and the symbi-
otic bacteria isolated from the actinomy-
cotic lesions to determine the proper drugs 
to be administered has been stressed. 
Nocardiosis 
~ocardiosis is closely akin to actinomy-
cosis clinically and mycologically, but with 
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enough differences to separate it from the 
latter condition as a distinct entity. The 
causative organisms belong to the ~ocardia 
genus which is widely distributed in nature 
and frequently isolated from soil. There are 
at least five species known to be pathogenic 
to man,217,218 including Nocardia asteroides, 
N orcal'dia brasiliensis, N orcardia madurae, 
and Nocardia pelletieri. By far the most 
common is Nocardia asteroides. These or-
ganisms are gram positive, variably acid 
fast branching filaments, readily fragment-
ing into bacillary and coccoid forms. They 
grow aerobically. 
The disease is world-wide in distribution 
with no racial preference. The source of in-
fection is exogenous. The most frequent 
portal of entry is the respiratory tract and, 
less commonly, the injured skin and the gas-
trointestinal tract. Thus, many of the cases 
(about 75 per cent) reveal pulmonary in-
volvement. The pulmonary form presents 
the clinical picture of acute or chronic pneu-
monitis, with a propensity for hematogen-
ous dissemination to other organs, particu-
larly the central nervous system. Once the 
central nervous system becomes involved, 
which occurs in about 30 per cent of the 
cases, the pulmonary complaints are over-
shadowed by signs and symptoms simulat-
ing brain tumor, brain abscess, or meningi-
tis, and the prognosis becomes graver. The 
disease may be acute and fulminating, caus-
ing death in a few days, but generally it 
tends to be chronic, with remissions and ex-
acerbations lasting for even up to 3 to 4 
years. The average duration is 6 months. 
A chronic and localized form of nocardi-
osis involving the skin and subcutaneous 
tissues constitutes a certain percentage of 
the incidence of maduromycosis or myce-
toma. The granules found in the discharge 
from the multiple draining sinuses and fistu-
las are smaller and softer than the "sulfur 
granules" of actinomycosis. They are col-
ored black, red, orange, or yellow and do 
not present clublike terminal structures at 
the periphery. 
In many cases the diagnosis of nocardio-
sis was made only after operation, very late 
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in the course of the disease, or at the au-
topsy table. Definite diagnosis can be made 
only with the laboratory demonstration of 
the organism. 
Treatment. The particular importance of 
early diagnosis and institution of treatment 
in nocardiosis has been emphasized, in view 
of the remarkable clinical efficacy of the sul-
fonamides, especially sulfadiazine. Most of 
the unsuccessful clinical trials with sulfona-
mides were blamed on the failure to estab-
lish an etiological diagnosis and start medi-
cation before the disease had become 
disseminated and progressed to an ad-
vanced stage. The sensitivity of Nocardia 
asteroides to sulfonamides has been amply 
confirmed in vitro219-224 and in viV0207,261 
and by apparent clinical cures achieved. 
The effective blood serum level of sulfadi-
azine is 10 to 20 mg. per 100 ml. with daily 
oral doses of 6 to 10 Gm. maintained over 
prolonged periods of time from 3 to 6 
months or longer. 
The sulfonamides have usually been used 
in conjunction with other measures, such as 
surgical intervention, x-rays, iodides, thy-
mol, broad-spectrum antibiotics, and even 
penicillin (which has been shown to be in-
effective, in contrast to its success in the 
management of actinomycosis). In the 
choice of antibiotics and other chemothera-
peutic agents, in vitro sensitivity tests may 
be misleading, for their results do not seem 
to correlate with those of clinical experi-
ence. A patient with pulmonary nocardiosis 
described by Rivera223 failed to respond to 
tetracycline but improved with chloram-
phenicol, although in vitro the isolated No-
cardia was found to be sensitive to tetracy-
cline and resistant to chloramphenicol. Both 
Runyon222 and Halde and N ewstrand216 
found streptomycin to be effective in vitro, 
but inactive in animal experimental infec-
tions. Nonetheless, sensitivity tests are still 
considered useful by the latter authors. In 
general, the clinical results with antibiotics 
and other agents like isoniazid, pregnenol-
one acetate, or stilbamidine without sulfon-
amides have been variable. 
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The sulfones have been shown to be ac-
tive against the Nocardias.216.225-227 Gon-
z:Hez Ochoa and his group, who have spear-
headed these investigations, worked on the 
premise that Promin, Promizole, and Dia-
sone act in vivo mainly by breaking down 
into 4,4' -diaminodiphenyl sulfone (DDS). 
They concentrated on DDS and found it 
effective, particularly in infections with N 0-
cardia brasiliensis. Of 21 patients with 4 
year follow-up periods, 15 were cured and 
6 showed marked improvement. The treat-
ment was prolonged: at least 2 years of 
daily oral administration of 200 mg. Prema-
ture withdrawal of the drug led to relapses 
which were much more resistant to subse-
quent treatment. The drug was also injected 
locally into the tumor mass or into the fistu-
las in 2 ml. amounts of 20 per cent solution 
daily. In spite of the long-term administra-
tion, surprisingly few serious toxic reactions 
appeared, except for secondary anemia 
which was easily controlled with iron ther-
apy. 
Surgical intervention is still definitely in-
dicated in the management of nocardial in-
fections, particularly in the mycetomatous 
form.228 Drainage of abscesses and excision 
of involved tissues are important adjuncts 
to sulfonamide therapy. 
Sporotrichosis 
Sporotrichosis is most often a subcutane-
ous rather than a systemic or deep fungus 
infection. The disease normally assumes the 
rather typical clinical appearance of an ul-
cerating, granulomatous, chancriform le-
sion, occurring at the site of direct cu-
taneous inoculation. The development of 
satellite lymphangitis and nodules occur-
ring along the inflamed lymphatics is also 
typical of the disease. The marked varia-
tions which occasionally occur in the cuta-
neous and subcutaneous forms of sporotri-
chosis demand that all clinicians maintain a 
high index of suspicion for this particular 
fungus disease. Systemic involvement may 
develop from Sporotrichum schenckii infec-
tion from a cutaneous site. Involvement of 
almost any organ with sporotrichum may 
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occur. It has been reported in the kidneys, 
testicles, epididymis, muscles, bones, joints 
and tendons, lungs, central nervous system, 
and tracheobronchial lymph nodes.25 
Sporotrichum schenckii is found with 
great difficulty on microscopic examination 
of stained or unstained clinical material. 
A positive diagnosis of sporotrichosis can 
be established only by culture of Sporo-
trichum schenckii on suitable media. For-
tunately, this organism is not fastidious in 
its nutritional requirements, and a brown-
ish to blackish, wrinkled, leathery-appear-
ing colony grows out readily on routine 
Sabouraud's glucose agar at room tempera-
ture, while a white, wrinkled, cerebriform, 
bacteria-like colony develops on the blood 
agar cultures at 37° C. This latter culture 
exhibits the budding yeast phase growth of 
the organism, while the room temperature 
culture exhibits hyphal growth with clusters 
of typical small pyriform conidia. 
Treatment. The iodides have become 
well established as the treatment of choice 
for sporotrichosis of all types.25 Invariably, 
a favorable response can be obtained by the 
oral administration of increasing doses of a 
saturated solution of potassium iodide. The 
initial dose should be approximately 5 drops 
given 3 times a day. This may be increased 
by one drop per dose, if a rapid increase is 
desired, or one drop per day otherwise, 
until the dosage of 40 to 50 drops 3 times a 
day is attained. This amount should be 
maintained for at least 2 to 3 weeks beyond 
the time that complete clinical healing has 
occurred. The patient should be instructed 
that clinical improvement is not to be ex-
pected until the iodides have been given 
for 2 to 3 weeks' time. Only rarely is this 
form of therapy ineffective in producing 
complete cure of any type of sporotrichosis. 
It is puzzling that the iodides have such ef-
fect on this fungus, for there is no evidence 
of increased uptake of radioactive iodine at 
the site of sporotrichotic lesions in the skin. 
The organism also grows in artificial media 
oontaining 10 per cent concentration of po-
tassium iodide.25 The iodides will not pre-
vent experimental infection of the rat, al-
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though they will effect cure of rat sporo-
trichosis, if continued in adequate dos-
age.229 
The aromatic diamidines, and particu-
larly 2-hydroxystilbamidine, deserve consid-
eration in the therapy of systemic sporotri-
chosis. An excellent· in vitro effect against 
Sporotrichum schenckii has been demon-
strated,152,230 and sporotrichosis has success-
fully been treated with stilbamidine.231 One 
case of central nervous system sporotri-
chosis has been treated with 2-hydroxystil-
bamidine.232 This patient was not able to 
tolerate the aromatic diamidine and died 
of renal insufficiency coincident with the 
drug therapy. Necropsy revealed healing 
lesions of sporotrichosis. We have seen a 
patient with sporotrichotic involvement of 
a knee joint who had a relapse following 
2-hydroxystilbamidine therapy. This patient 
was re-treated with amphotericin B in 
amounts of 50 mg. administered by slow in-
travenous drip in 500 C.c. of 5 per cent glu-
cose in water at daily intervals. A total dose 
of 0.5 Gm. was given. Following this ther-
apy, the sporotrichotic arthritis was no 
longer evident, and cultures of the joint 
space were negative for Sporotrichum 
schenckii. We have since learned that this 
patient has suffered a clinical relapse of the 
joint sporotrichosis. Amphotericin B has a 
high in vitro inhibiting effect on Sporotri-
chum schenckii.1 ,102 It is probable that this 
antibiotic would be effective in causing 
prompt cure of the usual type of uncompli-
cated lymphatic sporotrichosis. It is doubt-
ful that this toxic antibiotic should be given 
for the routine, benign forms of sporotri-
chosis. 
Candidiasis 
Candidiasis is not usually considered one 
of the deep or systemic mycoses. This dis-
ease (which was previously called monili-
asis) is caused by members of the genus 
Candida, usually Candida albicans. This 
yeastlike fungus can be isolated from nor-
mal stool, the vagina, the oral mucous mem-
brane, the skin, and even the normal ex-
ternal auditory canal,233 It is normally the 
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cause of superficial infection in mucous 
membranes of the mouth, the vagina, the 
paronychial skin, as well as the glabrous 
skin of the warm, intertriginous areas of the 
body. Candida albicans is rarely reported 
as the cause of truly systemic disease. Its 
incidence has sharply increased, however, 
with the increased usage of broad-spectrum 
antibiotics and the steroid hormones. These 
two categories of therapeutic agents have in-
creased human susceptibility to systemic in-
fection with Candida albicans.234-237 Since 
the fungus is often not pathogenic, there is 
also a problem associated with the clinical 
interpretation of the laboratory isolation of 
Candida albicans from such clinical sources 
as sputum, urine, skin and nail scrapings, 
nasopharyngeal scrapings, and gastric con-
tents. The finding of Candida albicans or 
other species of Candida on blood culture 
leaves no question as to pathogenicity.235 
The members of the Candida genus are 
easily cultured on almost any of the stand-
ard bacteriologic agars or media. Candida 
albicans is separated from the other species 
of Candida by the findings of terminal 
chlamydospores in the submerged portion 
of the culture when grown on corn meal 
agar. The finding of hyphal growth along 
with the single-budding blastospores in 
sputum, scrapings of skin or mucous mem-
branes, and urine is quite significant, and 
probably indicates that this yeastlike fungus 
has assumed the role of a true pathogen. 
Candida albicans is a pathogenic oppor-
tunist and is found as a superimposed in-
fection in individuals with debilitating dis-
eases, pregnancy, uncontrolled diabetes 
mellitus, the avitaminoses, and, as previ-
ously mentioned, those who are receiving 
long-term steroid or intensive antibiotic 
therapy. There is no reliable skin test which 
can be performed to aid in the diagnosis of 
candidiasis, and even though agglutinins 
have been demonstrated as part of systemic 
candidiasis, their presence has not been re-
liably consistent. 
Treatment. Two antifungal antibiotics 
must be given consideration in the treat-
ment of systemic candidiasis. Nystatin and 
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amphotericin B have both demonstrated ex-
cellent in vitro and in vivo effect against 
Candida albicans.12.35.5o.235.237-243 Nystatin, 
an antibiotic substance obtained from a 
species of streptomyces, is very effective in 
curing candidiasis when it is possible to 
apply the antibiotic directly to the causative 
fungus. This is quite possible when the pa-
tient has infection of the skin or mucocuta-
neous junction, the mouth or pharynx, the 
vagina, or the gastrointestinal tract.237.240.243 
Unfortunately, nystatin is very poorly ab-
sorbed from the gastrointestinal tract, and 
it is impossible to obtain adequate blood 
levels of this drug when given by this route. 
Nystatin has not proved effective in con-
trolling or curing pulmonary or broncho-
pulmonary candidiasis or Candida septice-
mia. There is one report235 of systemic can-
didiasis complicating bacterial endocarditis 
with apparent cure following the use of in-
tramuscular nystatin in the dose of 9.6 mil-
lion units administered over a 16 day pe-
riod. Unfortunately, nystatin given intra-
muscularly causes marked pain, swelling, 
and abscess formation at the site of injec-
tion. This form of the antibiotic is no longer 
available. H.owever, nystatin is, without 
question, the drug of choice for candidiasis 
.of any type when it is possible to use the 
antibiotic in ointment, lotion, mouth wash, 
wet dressing, suppository, or tablet form. 
Amphotericin B administered intraven-
ously must be considered as the probable 
therapy of choice for pulmonary candidasis 
and Candida septicemia. Like nystatin, 
amphotericin B is very poorly absorbed 
from the gastrointestinal tract when given 
orally. Also, like nystatin, amphotericin B 
produces a marked decrease in the number 
of Candida albicans organisms in the gastro-
intestinal tract, even when it is administered 
with a broad-spectrum antibiotic such as 
tetracycline.12 There is but one report of the 
use of intravenous amphotericin B in sys-
temic candidiasis. Utz, Treger, McCullough, 
and Emmons50 report the use of this anti-
biotic in 4 cases. Three of the 4 patients 
had previously undergone major surgical 
procedures; 2 developed Candida endocar-
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ditis following cardiac surgery, and one de-
veloped meningeal candidiasis following 
an operation for the insertion of a Holter 
valve to relieve a noncommunicating hydro-
cephalus. The 3 surgical patients died of 
candidiasis; however, it is doubtful that 
they received an adequate trial of ampho-
tericin B therapy. In a fourth case reported 
by the same authors Candida sepsis fol-
lowed cystoscopy and retrograde pyelo-
gram for a renal calculus. Blood and urine 
cultures were positive for Candida albicans. 
Complete recovery ensued after the patient 
was given a total of 110 mg. of amphotericin 
B over a 4 day period of time. There is good 
indication that amphotericin B is effective 
in the most serious forms of candidiasis. 
Two other chemotherapeutic agents de-
serve definite consideration in the treatment 
of systemic candidiasis. A saturated solution 
of potassium iodide has been used for many 
years as an adjunct in the treatment of all 
types of candidiasis.25 This should be given 
orally. The initial dose is 5 drops 3 times a 
day following meals, with increments of one 
drop for each dose, until the total dose of 
20 drDps 3 times a day is reached and main-
tained. Weare dubious .of any true benefit 
tD be obtained in systemic candidiasis frDm 
potassium iDdide therapy. The careful intra-
venDUS administratiDn .of methylrosaniline 
chloride (gentian violet) appears still tD be 
worthy .of cDnsideration.244,245 While the 
tDpical application .of this dye was the chief 
means .of cDntrDlling superficial candidiasis 
prior to the develDpment .of nystatin, meth-
ylrDsaniline chlDride is recommended in in-
travenDUS dosage .of 5 mg. per kilogram of 
bDdy weight, given every other day for 7 
tD 10 days. CDncentratiDn of the dye shDuld 
not exceed 0.5 per cent and the solution 
should be filtered thrDugh a Berkefeld or 
Seitz filter. 
A host of .other chemotherapeutic agents 
have been advocated fDr the treatment .of 
cutaneDUS and systemic candidiasis. These 
include such agents as fatty acid, resin com-
plex,246 the para-aminD benzoic acid es-
ters,247 vitamin B complex, brilliant cresol 
green, the arDmatic diamidines, testDster-
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.one, methyltestDsterDne, testosterone prD-
pionate, and even brDad-spectrum antibi-
otics.248 It should be mentioned, also, that 
the new antifungal antibiDtic, griseDfulvin, 
has shown no in vitro nor in vivo effect 
against Candida albicans or other members 
of the candida genus. We have had occa-
sion to use griseofulvin in widespread cu-
taneDUS candidiasis and have not .observed 
beneficial effect. 
Aspergillosis 
The aspergilli abDund in nature. PalinD-
logic surveys have shDwn the prevalence 
.of their anemDphilic spDres in the atmDs-
phere, where they form .one of the aerobio-
logic factors causing inhalant allergy. The 
fungus is well known as a saprDphyte but 
can be parasitic to plants, birds, and occa-
sionally, mammals. Of the more than 375 
species described, .only a few have been 
iSDlated as pathogens for man: Aspergillus 
fumigatus, by far the mDst common; Asper-
gillus glaucus; Aspergillus flavus; Aspergil-
lus niger; and Aspergillus nidulans. 
The fungDus grDwth is mycelial and char-
acterized by a knDblike fruiting body to 
which numerous conidia are attached. The 
tissue form is morphologically the same as 
the saprDphytic phase. 
For reaSDns still not known exactly, the 
fungus occasionally acquires the ability to 
invade tissues, causing granulomatous le-
sions in the lungs, skin, external ears, nasal 
sinuses, nails, central nervous system, eyes, 
bones, and vagina. The organism may be a 
primary or secondary invader. The sympto-
matology varies with the areas involved, 
such as that of pneumonitis, .onychomycosis, 
otitis externa, or maduromycosis. The most 
common fDrm is otomycosis, but pulmonary 
aspergillosis has gained more medical in-
terest. Primary pulmonary aspergillosis is 
usually regarded as an occupational disease 
among individuals unduly exposed to the 
spores. A significant number of cases of pul-
monary aspergillosis is superimposed as a 
secondary infection on other diseases, such 
as tuberculDsis, carcinoma, bronchiectasis, 
or infarction. The infection is rarely dissem-
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inated.249 The clinical picture is that of 
tracheobronchitis, bronchopneumonia, tu-
berculosis, or tumor. The x-ray findings vary 
considerably and may show a "sunburst ef-
fect," evidence of pneumonic or broncho-
pneumonic consolidation, cavitation, or, 
rarely, a diagnostic solitary density whose 
superior border is outlined by a thin, cres-
cent-shaped area of radiotranslucency. 
A definitive diagnosis of aspergillosis is 
difficult to make and cannot be established 
on clinical grounds alone. It depends on the 
demonstration of the organism from the 
clinical material. Even the cultural isolation 
of the fungus does not answer the question 
of whether the isolated organism is a path-
ogenic invader or a oontaminant. The diag-
nostic criteria are repeated isolations of the 
aspergillus in pure cultures from the lesions 
and its demonstration histopathologically 
with the surrounding tissue reaction of the 
body. 
Together with infections due to organ-
isms generally known as saprophytes, like 
Mucor, Candida, Geotrichum, and Penicil-
lium, aspergillosis has increased in inci-
dence associated with the present-day ex-
tensive use of steroids and broad-spectrum 
antibiotics.250,251 Sidransky and Friedman250 
made mice highly susceptible to fatal pul-
monary aspergillosis by treatment with ster-
oids and antibiotics. The inhaled spores 
failed to germinate into hyphae in the oon-
trol mice, but did so readily in the treated 
animals. The steroids apparently were more 
responsible. 
Treatment. There is no consistently effec-
tive medical control .. The noted increased 
incidence of aspergillosis has made the 
search for the ideal chemotherapeutic agent 
more imperative. The occasional favorable 
results obtained with sulfonamides, penicil-
lin, streptomycin, and other antibiotics were 
attributed mainly to their action on concom-
itant bacterial infections. 
The in vitro sensitivity of Aspergillu8 
fumigatus to certain antibiotics and chemo-
therapeutic agents has occasionally been 
studied.252.253 The marked sensitivity of the 
organism to mercuric iodide red was noted. 
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Penicillin was inactive in concentrations up 
to 125 ",g per milliliter of medium, but in-
hibited fructification above this concentra-
tion. Even at 10 mg. per milliliter of me-
dium, the broad-spectrum antibiotics suc-
ceeded only in preventing fructification. 
There is a paucity of clinical reports on 
adequate therapeutic trials in aspergillosis 
because of the difficulty of establishing a 
preoperative or antemortem diagnosis. As a 
result, the data are grossly insufficient and 
the conclusions as to the value of the drugs 
tested are at most preliminary. 
The aromatic diamidines were tried in a 
few cases. Ridde1l254 stated that, in his ex-
perience, inhalation of 2-hydroxystilbami-
dine solutions was effective in removing 
Aspergillus fumigatu8 from bronchial secre-
tions. Stevenson255 reported a case of pul-
monary aspergillosis which responded sat-
isfactorily to two courses of 10 intravenous 
injections of 150 mg. of 2-hydroxystilbami-
dine given daily. This therapy was followed 
by a course of oral nystatin. The patient, 
however, died later with renal failure. A pa-
tient with primary pulmonary aspergillosis' 
described by Librach256 did not respond to 
treatment with 2-hydroxystilbamidine as 
well as to iodides, isoniazid, streptomycin, 
penicillin, and oxytetracycline. Hi n son, 252 
on finding that Aspergillu8 fumigatus was 
inhibited in vitro by diamidinodiphenyla-
mine (M & B 938) in a concentration of 
1: 100,000, tried the drug clinically in a case 
of pulmonary aspergillosis. The patient 
showed only slight equivocal improvement 
and severe toxic hypotensive symptoms 
with administration of the drug. 
The agent being sought for the effective 
control of aspergillosis most probably will 
be found among the antifungal antibiotics 
that are being introduced in increaSing 
numbers. Ridde1l254 also mentioned the ef-
fective use of nystatin inhalation. Steven-
son's255 patient also received nystatin, 500,-
000 units given thrice daily for 8 weeks, 
after two courses of 2-hydroxystilbamidine. 
In the successful treatment of a case of hy-
popyon keratitis due to Aspergillus fumi-
gatus, Mangiaracine257 believed that ny-
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statin administered locally and systemically 
exerted a beneficial effect. Manning and 
Robertson258 recently described a case of 
pyopneumothorax due to a secondary infec-
tion with Aspergillus fumigatus after a his-
tory of treated pulmonary tuberculosis and 
a bout of secondary pneumococcal infection 
for which the patient had received a course 
of tetracycline. Nystatin was administered 
by intrapleural instillation of 500,000 units 
daily. The patient received 15.5 million 
units in 38 days and improved remarkably, 
with no side effects due to the drug. The 
organism disappeared from the sputum. A 
concomitant secondary infection with 
Staphylococcus aureus was controlled with 
daily intrapleural administration of 0.5 Gm. 
chloramphenicol. 
An antifungal antibiotic that deserves 
clinical trial in aspergillosis is griseofulvin, 
which has aroused interest because of its 
efficacy in the treatment of dermatomycosis 
by the oral route.259,260 Its inhibitory effect 
on filamentous fungi with chitin cell walls 
which include the aspergilli is most spe-
cific.261 The antibiotic is relatively nontoxic 
in therapeutic doses. It is not unreasonable 
to predict that favorable results will be ob-
tained with the use of griseofulvin in asper-
gillosis, particularly in its otomycotic and 
onychomycotic forms, in view of its affinity 
for keratinous tissues. 
In the absence of successful medical 
treatment in aspergillosis, emphasis is laid 
on the surgical approach. This is mainly 
excisional in nature, and most reports of ap-
parent cures in aspergillosis deal with the 
resection of localized lesions, such as asper-
gillomas.262-264 
Mucormycosis 
Systemic disease produced by members 
·of the order Mucorales is referred to as a 
mucormycosis, even though members of the 
genera Rhizopus, Absidia, and others, be-
sides the genus Mucor, may cause the dis-
ease. The name mucormycosis is quite ac-
ceptable when used in this manner. This is 
fortunately a rare mycotic disease, which 
usually develops in individuals who have 
Treatment of systemic fungus diseases 125 
uncontrolled diabetes mellitus. The disease 
was first reported by Paltauf265 in 1885. 
Since that time, there has been a total of 
24 cases of mucormycosis reported in the 
world's literature.266,267 A complete sum-
mary of the reported cases of mucormyoosis 
is available.266 
The members of the order Mucorales 
most commonly found to produce mucor-
mycosis are Rhizopus sp. and Muoor sp. 
Both of these fungi occur as common labor-
atory contaminants, and are known as 
"sugar fungi."268,269 The hyphae of these 
fungi exhibit few or no septations and pos-
sess the ability to break down sugar. It is 
of interest that they have been found to be 
most pathogenic in diabetic individuals. 
They grow at a very rapid rate and, when 
contamination with Mucor sp. or Rhizopus 
sp. occurs, it takes but a few days for the 
aerial growth of the organisms to fill com-
pletely all the available space of the culture 
tube. The tendency toward such rapid 
growth has been exhibited clinically when 
these contaminant fungi assume pathoge-
nicity. Extension through the orbit or para-
nasal sinuses to the cerebral vessels has 
occurred in the vast majority of cases,266,269 
and in most instances death has occurred 
within a matter of days from the time symp-
toms have been reported. The syndrome 
consisting of diabetes mellitus, ophthalmo-
plegia, signs of meningoencephalitis, and 
possibly sinusitis should make one consider 
the diagnosis of cerebral mucormycosis.269 
There are no instances of successful at-
tempts at chemotherapy for mucormycosis. 
A case has recently been reported266 in 
which potassium iodide, given during a 48 
hour period prior to death, had no bene-
ficial effect. Unfortunately, this disease is 
usually diagnosed post mortem, and ampho-
tericin B has not been given an adequate 
trial. This antifungal antibiotic should be 
given a therapeutic trial in any individual 
in whom the antemortem diagnosis of mu-
cormycosis has been established. Chick270 
has treated experimentally produced mucor-
mycosis in rabbits with amphotericin B. 
The drug was found to protect a rabbit 
126 Harrell and Bocobo 
which had been given a standardized lethal 
dose of Rhizopus spores. Also, the drug ap-
parently inhibited the transformation of 
spores into hyphae, when injected intrave-
nously. The animals that were sacrificed 
following such injections were found to be 
virtually free of evidence of visceral infec-
tion. These experiments suggest that am-
photericin B may be of great value in the 
treatment of human mucormycosis. 
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